| 应益昕,王 健,王晔博,欧阳进良.欧洲药物创新计划实施对我国药物研发计划的启示[J].全球科技经济瞭望,2020,35(2):35~39 |
| 欧洲药物创新计划实施对我国药物研发计划的启示 |
| European Innovative Medicines Initiative Plan and Its Implication for theInnovation of China’s Pharmaceutical Plan |
| 投稿时间：2020-01-09 |
| DOI：10.3772/j.issn.1009-8623.2020.02.007 |
| 中文关键词: 药物创新计划；管理体系；任务部署 |
| 英文关键词: Innovative Medicines Initiative; management system; task deployment situation |
| 基金项目:科技部科技创新战略研究专项“国家科技重大专项验收机制和验收指标体系研究”（ZLY201724）。 |
|
| 摘要点击次数: 2450 |
| 全文下载次数: 1946 |
| 中文摘要: |
| 欧洲药物创新计划（IMI）于2008年启动，经过十余年部署实施，取得系列重要进展和成效，对于推动欧洲创新药物研发发挥了重要作用。本文系统分析IMI的实施背景与目的、管理体系、布局部署及其成效影响等，以期为我国药物研发计划的组织实施提供借鉴与参考。 |
| 英文摘要: |
| Innovative drug research and development is a strategic area for competition among developed countries. The European Innovative Medicines Initiative Plan was launched in 2008 and has made important progress in the field of innovative drug research. This paper systematically sorts out the background and purpose, the management system, the task deployment situation, the impact of the implementation of European Innovative Medicines Initiative Plan, etc., and provides reference for the organization and implementation of China's drug research and development plan. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
